Cipla Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.3 pts more than Nifty 100 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Cipla reported consolidated revenue from operations of ₹6,957.47 crores in Q1FY26, up about 3.9% from ₹6,693.94 crores in Q1FY25. Consolidated net profit rose roughly 9.9% to ₹1,291.61 crores from ₹1,175.46 crores, with EPS at ₹15.13 versus ₹14.58. On a standalone basis, revenue grew about 12.1% to ₹5,046.17 crores and net profit jumped roughly 23.4% to ₹1,303.13 crores, with standalone EPS of ₹16.13. The Pharmaceuticals segment contributed ₹6,579.42 crores in revenue, while the New Ventures segment turned profitable at ₹56.76 crores compared with a small loss a year ago. The auditor (Walker Chandiok & Co LLP) issued an unmodified limited review conclusion on both sets of results.
Steady, broad-based growth with margin expansion at the standalone level, driven by both the core Pharma and improving New Ventures businesses — likely to be viewed positively by investors. No new exceptional items in the quarter and a clean auditor opinion remove near-term concerns, though the long-standing NPPA overcharge matter (aggregate exposure of around ₹2,011 crores) remains an overhang worth watching.